Prot # WA21092/B: A Randomized, Double-blind, Double Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a(Rebif®)in Patients with Relapsing Multiple Sclerosis

Project: Research project

Project Details

StatusActive
Effective start/end date3/23/1212/31/22

Funding

  • Quintiles, Inc. (Prot # WA21092/B)
  • Genentech, Inc. (Prot # WA21092/B)